Insmed reports Q4 2022 ARIKAYCE revenue $59.3M, full year $245.4M; net loss $1.21 per share

INSMED Inc

2022-FY EPS reported -$3.91 revenue$245,358,000

ARIKAYCE global revenue grew 30% in 2022 to $245.4M; Q4 revenue $59.3M, impacted by $7.5M French pricing adjustment.
Net loss for Q4 2022 was $160.1M ($1.21/share) vs $113.0M ($0.95/share) in Q4 2021; full year net loss $481.5M ($3.91/share).
Phase 3 ASPEN trial of brensocatib in bronchiectasis completed adult patient screening; topline data expected Q2 2024.
Company guides 2023 ARIKAYCE global revenue $285-300M; cash position $1.15B as of Dec 31, 2022.
ARISE study topline data expected Q3 2023; ENCORE enrollment by end 2023; early-stage research update May 8, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INSMED Inc reported the fourth quarter ended December 31, 2022 results: revenue $59.3 million, net income net loss of $160.1 million, EPS $1.21 per share.

Period: the fourth quarter ended December 31, 2022
Revenue: $59.3 million
Net income: net loss of $160.1 million
EPS: $1.21 per share
Result: reported results

Exact text from the filing

on Track to Share Topline Data from Post-Marketing ARISE Study of ARIKAYCE ® (amikacin liposome inhalation suspension) in Third Quarter of 2023— —ARIKAYCE Total Revenue of $59.3 Million for the Fourth Quarter and $245.4 Million for the Full Year 2022, Reflecting 30% Annual Growth— BRIDGEWATER, N.J., February 23, 2023 /PRNewswire/ — Insmed Incorporated

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INSMED Inc reported the full year ended December 31, 2022 results: revenue $245.4 million, net income net loss of $481.5 mill.

Period: the full year ended December 31, 2022
Revenue: $245.4 million
Net income: net loss of $481.5 mill
Result: reported results

Exact text from the filing

Total revenue for the full year 2022 was $245.4 million, compared to total revenue of $188.5 million for the full year 2021.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

INSMED Inc filing history →

Source: SEC EDGAR

accession 0001140361-23-008163

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.